EASD 2022

2022 ADA/EASD consensus report on management of hyperglycemia in T2DM
2022 ADA/EASD consensus report on management of hyperglycemia in T2DM
EASD 2022
2022 ADA/EASD consensus report on management of hyperglycemia in T2DM
- Prof. John Buse, MD, PhD
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
EASD 2022
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
- Pardeep Jhund, MD, PhD
Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i
Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i
EASD 2022
Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i
- Marta Seghieri, MD
Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage
Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage
EASD 2022
Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage
- Prof. Peter Rossing, MD